Antidepressant exposure in the womb now looks far less alarming than many parents have been led to believe. A large observational study reports little to no increase in childhood attention-deficit/hyperactivity disorder or autism spectrum disorder once family history and maternal mental health are rigorously controlled.
Researchers argue that earlier fears were overstated, because they blurred medication effects with the underlying biology of depression and anxiety. Using registry data and sibling comparisons, the team separated drug exposure from shared genetics and environment, a design that sharply reduces confounding and mimics some strengths of randomized allocation.
Clinicians see a practical message here. Risk from untreated major depression, including impaired prenatal care and elevated cortisol, can be substantial, while the incremental neurodevelopmental risk from serotonin reuptake inhibitors now appears minimal within statistical uncertainty. For obstetric and psychiatric teams, the study supports individualized risk–benefit discussions rather than reflexive discontinuation.
The findings will not end debate over psychopharmacology in pregnancy, but they redraw its center of gravity toward the illness itself, not just the prescription bottle.
